In a nutshell This study wanted to see how well two medications worked in treating advanced triple negative breast cancer, atezolizumab (Tecentriq) and nab-paclitaxcel (Abraxane). The study found that using these two medications together improved survival in these patients. Some background Triple-negative breast cancer (TNBC) is breast cancer...
Read MoreIn a nutshell This study wanted to find out if removing the main tumor in women with cancer that has spread to other organs leads to greater survival than not removing the main tumor. The study found that the patients who had the surgery survived 47% longer than patients without the surgery. Some background Breast cancer can sometimes be caught quite...
Read MoreIn a nutshell This trial is examining the effectiveness of atezolizumab (Tecentriq) when used with chemotherapy in patients with inoperable, recurrent triple-negative breast cancer. The main outcome to be measured will be the overall survival (time from treatment until death from any cause) of participants. The...
Read More
In a nutshell This trial is examining the effectiveness of tesetaxel plus a reduced dose of capecitabine for hormone receptor (HR) positive/HER2 negative advanced breast cancer. The main outcome to be measured will be progression free survival (time from treatment until disease progression). The details Breast cancer is classified into...
Read MoreIn a nutshell This trial is examining the effectiveness of chemotherapy and atezolizumab (Tecentriq), given before surgery, for triple negative breast cancer. The main outcomes to be measured will be response in the breast tissue and lymph nodes and survival. The details Triple negative breast cancer is not dependent on the HER2 receptors or...
Read MoreIn a nutshell This trial is examining the effectiveness of a whole food diet for women with stable metastatic (spread) breast cancer currently undergoing treatment. The main outcomes to be measured will be the recruitment of patients approached, adherence to diet and change in symptoms and biomarkers. This study is being...
Read More
In a nutshell This phase 2 trial aims to test the effectiveness of the combined treatment of three different immunotherapies. The main outcomes of this trial will be the tumor response to the treatment and the overall survival. The details Immunotherapies stimulate the immune system to attack and kill cancer cells the way it would a virus or...
Read More
In a nutshell This study investigated the effect of nivolumab (Opdivo) in patients with progressive melanoma after ipilimumab (Yervoy) treatment. Researchers suggested that nivolumab treatment is associated with better response compared with chemotherapy. Some background Recent new therapies, such as immunotherapy, have changed the treatment of...
Read More
In a nutshell This study looked at the safety and effectiveness of isolated limb infusion in elderly patients with melanoma of the skin on a limb (arm/leg) that could not be surgically removed. The study found isolated limb infusion to be safe and effective in elderly patients. Some background lsolated limb perfusion (ILP) is a method of...
Read More
In a nutshell This study aimed to compare fulvestrant (Faslodex) to other standard endocrine agents in patients with advanced hormone sensitive breast cancer. This study concluded that fulvestrant was as effective as the available standard endocrine agents. Some background Advanced hormone sensitive breast cancer (BC) is cancer that has...
Read More
In a nutshell This study aimed to compare the effectiveness of the combination of fulvestrant (Faslodex) and abemaciclib to fulvestrant alone in patients with advanced breast cancer. This study concluded that the combination of fulvestrant and abemaciclib had improved outcomes for patients when compared to fulvestrant alone. Some background...
Read More
In a nutshell This study investigated the use of dexamethasone (Ozurdex) mouthwash for preventing stomatitis in patients with breast cancer(BC). The use of dexamethasone oral solution was found to significantly reduce the incidence and severity of stomatitis. Some background Everolimus (Afinitor) and exemestane (Aromasin) are mTOR inhibitors...
Read More
